Cellular Sciences, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
2
Ending by 2030
Aug 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 14, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,114,907 | Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells In force · From the USPTO record | In force | From the USPTO record | |
| US 8,211,943 | Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells In force (reinstated) · From the USPTO record | In force (reinstated) | From the USPTO record | |
| US 9,675,569 | Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells In force · From the USPTO record | In force | From the USPTO record | |
| US 10,813,893 | Compositions and methods for the treatment and prevention of chronic hypoxemia and dyspnea In force · From the USPTO record | In force | From the USPTO record | |
| US 11,628,186 | Method and composition for the reduction of viral replication, duration and spread of the COVID-19 and the flu In force · From the USPTO record | In force | From the USPTO record | |
| US 11,311,505 | Synergistic compositions to stimulate the synthesis of human lung and sinus surfactants to decrease coughing, increase FEV-1/FVC ratios, decrease lung fibrosis, by increasing apoptosis of myofibroblasts In force · From the USPTO record | In force | From the USPTO record | |
| US 12,611,389 | Compositions and Methods to Reduce or Eliminate Nasal Biofilms and Mucus Barriers Allowing Sodium Pyruvate to Increase the Synthesis of Nitric Oxide and Eliminate Nasal Infections and Their Toxins That Cause Lung, Nerve and Brain Damage In force · High confidence | In force | High confidence |
Also on record, not counted in the 7: 2 lapsed for an unpaid fee · 4 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 no status recorded